New diabetic drug to come to UAE

New diabetic drug to come to UAE

NeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.

Vildagliptin is an oral anti-diabetic agent that delivers consistent and robust blood sugar control in patients with type 2 diabetes. It is a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, which do not cause weight gain and have low risks for hypoglycaemia. 

The overall market for oral hypoglycaemic agents (OHA) in UAE is estimated to be USD 115 million and DPP-IV inhibitors command nearly 50% share of this market. A novel product, Vildagliptin is available both as monotherapy as well as in combination with metformin. Together Vildagliptin and Vildagliptin + Metformin commands over 30% of the DPP-IV market in UAE.

NeoBiocon has received approvals from the Ministry of Health-UAE for marketing Jalra and Jalra-M in the country and the launch is scheduled for Jan 2016.  These products will be manufactured by Novartis in Europe and marketed and distributed by NeoBiocon in UAE after local release through Neopharma.

Talking about the partnership, Dr. B. R. Shetty, Chairman, Neopharma, said: “We are delighted to extend our partnership with Novartis and Biocon for these novel products. Biocon’s leadership in the diabetes segment will augur well for marketing these brands in UAE.”

Commenting on the development, Dr Kiran Mazumdar-Shaw, CMD, Biocon, said: “Biocon is committed to offer advanced therapies for diabetics the world over. We are indeed pleased to partner with Novartis to offer Jalra and Jalra-M to address the growing needs of type 2 diabetes patients in UAE.”

The partnership between NeoBiocon and Novartis will benefit the large and increasing number of diabetics in the UAE.  This will result in enhancing access to this novel oral hypoglycaemic agent by leveraging the huge marketing network of NeoBiocon & distribution network of NMC Healthcare.  Novartis will continue to market its brands Galvus & Galvusmet in the UAE.

NeoBiocon is amongst the fastest growing pharmaceutical companies in UAE and is ranked amongst the top 25 pharma companies in the region. It is the no.1 generic pharma company in UAE, in the cardiovascular segment with successful brands like Statix (atorvastatin). NeoBiocon is committed to bring innovative products to the GCC market and enhancing capabilities of the local manufacturers. 

Established in 2011, NeoBiocon markets its own brands in UAE & other GCC markets in various therapies such as metabolics, oncology, asthma & allergic rhinitis, anti-infectives and others. Through this partnership with a multinational pharma company, NeoBiocon has further strengthened its resolve to create a positive impact in the lives of the patient’s through innovative products.





Amazon digital ad share on the rise

Amazon digital ad share on the rise

San Francisco : Online retail colossus Amazon is gaining ground in the US digital advertising market as the dominance of Google and Facebook erodes, according to an eMarketer forecast released on Wednesday. The market tracker predicted that Amazon will take in $4.61 billion in online a

GCC national in the dock for using illegal weapon

GCC national in the dock for using illegal weapon

A drunken GCC national fired bullets into the air to break up a fight started by him, it is learnt. The action landed him in police net as he is accused of using an illegal weapon. He was arrested after a police complaint was filed against him. The GCC man had initially denied using the g

Sony to release ‘classic’ PlayStation

Sony to release ‘classic’ PlayStation

Paris : Sony announced Wednesday it plans to launch a miniature games console designed like the original PlayStation pre-loaded with 20 vintage games as it joins the retro gaming craze just in time for Christmas. Dubbed the PlayStation Classic, the new console comes with a considerably

Verdict date set for man accused of killing father

Verdict date set for man accused of killing father

A Bahraini drug-addict on trial for killing his father will learn his fate on October 31, 2018, announced the High Criminal Court yesterday. This came after a mental report to determine his psychological state deemed him responsible for his actions. The report showed that the defendant wa

Woman earns court order to rejoin husband

Woman earns court order to rejoin husband

The Court of Urgent Matters ruled in favour of a Bahraini woman who wanted to rejoin her husband. According to court details, the woman left her husband a few months ago and since then she had been staying with her father. “Although she expected her husband to reconcile with her, it did not

Women’s collective on a rare cooking mission

Women’s collective on a rare cooking mission

More than 60 women gather every day in a small village on the western coast of the island for a special mission – cooking food for those who take part in mourning processions as part of the Ashoora rituals.  They prepare about 750 kg of food every day before distributing them t

Amazon, Samara buy India’s ‘More’

Amazon, Samara buy India’s ‘More’

New Delhi : Amazon.com Inc and Indian private equity firm Samara Capital have bought Aditya Birla Group-owned ‘More’ retail chain for an enterprise value of 42 billion rupees ($580.35 million), CNBC TV18 reported yesterday, citing sources. Amazon’s latest acquisition

Import ban on Julphar drugs

Import ban on Julphar drugs

Bahrain has stopped importing all drugs produced by the Gulf Pharmaceutical Industries (Julphar). The National Health Regulatory Authority (NHRA) has directed government departments and the main supplier of Julphar drugs to enforce the ban. In a statement issued yesterday, the authority said that

-->